Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 AGTC-402 gene therapy study in CNGA3-associated congenital achromatopsia
MOH_2018-06-24_000702Phase 2Recruiting
- Sponsor
- Applied Genetic Technologies Corporation
- Start
- Jun 2017
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of AGTC-402 in achromatopsia (ACHM) (4 cohorts), sponsored by Applied Genetic Technologies Corporation. Started Jun 2017; status: recruiting.
02
Drugs
AGTC-402
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on MOH_2018-06-24_000702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-24_000702.